CompanyNKTRNasdaqSan Francisco, CA

Nektar Therapeutics

Nektar Therapeutics develops treatments for autoimmune and chronic inflammatory diseases.

SEC EDGAR ClinicalTrials.gov nektar.com

8-KOct 1Latest SEC filing

Aug 13Latest story

August 2026

Nektar reports Q2 2026 results, details Phase 3 rezpegaldesleukin timeline

Aug 13Quarterly updateNektar Therapeutics rezpegaldesleukin

July 2026

Nektar registers Phase 3 "ZENITH AD-2" trial of rezpegaldesleukin in atopic dermatitis

Jul 17Trial updateNektar Therapeutics rezpegaldesleukin

Nektar registers Phase 3 atopic dermatitis trial for rezpegaldesleukin

Jul 8Trial updateNektar Therapeutics rezpegaldesleukin